23,620 Shares in Tharimmune, Inc. (NASDAQ:THAR) Bought by Curi RMB Capital LLC

Curi RMB Capital LLC purchased a new stake in Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune as of its most recent filing with the Securities & Exchange Commission.

Tharimmune Stock Performance

THAR opened at $2.17 on Friday. The firm’s 50-day moving average price is $2.44 and its 200-day moving average price is $3.35. Tharimmune, Inc. has a 52-week low of $1.84 and a 52-week high of $79.65.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).